) --

Talecris Biotherapeutics



) hit a new 52-week high Thursday as it traded at $26.52 compared with its previous 52-Week high of $26.51. Talecris is changing hands at $26.48 with 7,700 shares traded as of 9:37 a.m. ET. Average volume has been 1.2 million shares over the past 30 days.

Talecris has a market cap of $3.3 billion and is part of the

health care

sector and


industry. Shares are up 13% year to date as of the close of trading on Wednesday.

Talecris Biotherapeutics Holdings Corp., a biopharmaceutical company, engages in the production and marketing of plasma-derived protein therapies worldwide. The company has a P/E ratio of 20.1, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 16.

  • Practice your TLCR trading strategies and win cash in our stock game.

TheStreet Ratings rates Talecris as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and growth in earnings per share. However, as a counter to these strengths, we find that the company has not been very careful in the management of its balance sheet. You can view the full

Talecris Ratings Report


See all

52-week high stocks

or get investment ideas from our

investment research center